Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.
Science
; 384(6702): eadf1329, 2024 Jun 21.
Article
en En
| MEDLINE
| ID: mdl-38900877
ABSTRACT
Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti-PD-1 (programmed cell death protein 1) immunotherapy improves immune function and antitumor responses in mice and results in high response rates (67%) in a phase 2 clinical trial for metastatic non-small cell lung cancer. Patients who failed to respond to initial anti-PD-1 immunotherapy but responded after addition of itacitinib had multiple features of poor immune function to anti-PD-1 alone that improved after JAK inhibition. Itacitinib promoted CD8 T cell plasticity and therapeutic responses of exhausted and effector memory-like T cell clonotypes. Patients with persistent inflammation refractory to itacitinib showed progressive CD8 T cell terminal differentiation and progressive disease. Thus, JAK inhibition may improve the efficacy of anti-PD-1 immunotherapy by pivoting T cell differentiation dynamics.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Linfocitos T CD8-positivos
/
Janus Quinasa 1
/
Receptor de Muerte Celular Programada 1
/
Inhibidores de las Cinasas Janus
/
Inhibidores de Puntos de Control Inmunológico
/
Neoplasias Pulmonares
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Science
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos